Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281263 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults
A Phase 1 study, sponsored by Blue Lake Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05281263 is a Phase 1 study that has completed, run by Blue Lake Biotechnology. The registered enrollment target is 30 participants.
The verdict
NCT05281263, a Phase 1 study, has completed, sponsored by Blue Lake Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This Phase 1 trial is an open-label trial to evaluate the safety, tolerability and immunogenicity of a single dose (10\^7.5 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered as a single dose in 15 healthy young adults ages 18-59 years, and 15 older adults ages 60-75 years.
Interventions
- BIOLOGICAL CPI-RSV-F Vaccine (BLB-201)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2023-05-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05281263
The ClinicalTrials.gov registry entry for NCT05281263 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Blue Lake Biotechnology, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPI-RSV-F Vaccine (BLB-201) is the first listed.
NCT05281263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05281263 about?
NCT05281263 is a clinical study titled "Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults". This Phase 1 trial is an open-label trial to evaluate the safety, tolerability and immunogenicity of a single dose (10\^7.5 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered as a single dose in 15 healthy young adults ages 18-59 years, and 15 older adults ages 60-75 ...
What is the current status of trial NCT05281263?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-07-20. Estimated completion is 2023-05-03.
What interventions are being tested in trial NCT05281263?
The interventions under investigation include: CPI-RSV-F Vaccine (BLB-201) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05281263?
This trial is sponsored by Blue Lake Biotechnology, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.